---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-217945"
form_type: "8-K"
ticker: "VERU"
cik: "0000863894"
company_name: "VERU INC."
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T01:14:38.086344+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Veru Q3 net loss $22.2M on 46% revenue decline; sabizabulin EUA under FDA, UK, EMA review

## Summary
- Net loss of $22.2M ($0.28 per share) vs $2.7M loss a year ago; revenue $9.6M vs $17.7M.
- Sabizabulin EUA submitted to FDA June 2022; UK MHRA granted expedited review; EMA Emergency Task Force reviewing for EU emergency use.
- Phase 3 COVID-19 trial showed 55.2% relative reduction in deaths; results published in NEJM Evidence.
- ENTADFI (tadalafil/finasteride) commercially launched for BPH; FC2 prescription sales down 50% due to telemedicine customer issues.
- Cash and equivalents $100.6M as of June 30, 2022, down from $122.4M at Sep 30, 2021.

## SEC filing metadata
- accession: 0001193125-22-217945
- form_type: 8-K
- ticker: VERU
- cik: 0000863894
- company_name: VERU INC.
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/863894/000119312522217945/0001193125-22-217945-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/863894/000119312522217945/d393861d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-217945
- JSON: https://secwatch.observer/filing/0001193125-22-217945.json
- Plain text: https://secwatch.observer/filing/0001193125-22-217945.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.